Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director | August 02, 2017 | August 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAMED PHARMACEUTICALS INC.
Report date August 02, 2017 · Filed August 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 206,350 |
Reported balance
After 2017-08-02 transaction · row 1
1 source rowRow 1 · 2017-08-02 · Purchase · Acquired 89,636 · Balance 206,350 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2017 Filed Aug 3, 2017 22:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCOMMON STOCK | 89,636 | $8.50 | $761,906.00 |
DisclosureSEC source: 0001213900-17-008214 · f4080217li_oramed.xml · nonDerivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,350 Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:37 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007155 · f4063017li_oramed.xml · derivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 21:05 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 52,814 | $6.33 | $334,312.62 |
DisclosureSEC source: 0001178913-17-001172 · zk1719829.xml · nonDerivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,714 Read SEC document |
| February 09, 2017 Filed Mar 2, 2017 20:06 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 12,253 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-17-001939 · f4020917li_oramed.xml · derivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,253 Underlying: Common Stock · 12,253 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
| November 07, 2016 Filed Nov 7, 2016 19:27 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 63,900 | $7.42 | $474,138.00 |
DisclosureSEC source: 0001213900-16-018027 · f4110716xiaopeng_oramed.xml · nonDerivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,900 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.